DE69230183T2 - Quantitativer gerinnungstest für aktivierten faktor vii - Google Patents

Quantitativer gerinnungstest für aktivierten faktor vii

Info

Publication number
DE69230183T2
DE69230183T2 DE69230183T DE69230183T DE69230183T2 DE 69230183 T2 DE69230183 T2 DE 69230183T2 DE 69230183 T DE69230183 T DE 69230183T DE 69230183 T DE69230183 T DE 69230183T DE 69230183 T2 DE69230183 T2 DE 69230183T2
Authority
DE
Germany
Prior art keywords
factor
assay
viia
factor viia
factor vii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69230183T
Other languages
English (en)
Other versions
DE69230183D1 (de
Inventor
James Morrissey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of DE69230183D1 publication Critical patent/DE69230183D1/de
Publication of DE69230183T2 publication Critical patent/DE69230183T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/821—Chemistry: analytical and immunological testing involving complement factors or complement systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control
DE69230183T 1991-04-10 1992-04-09 Quantitativer gerinnungstest für aktivierten faktor vii Expired - Lifetime DE69230183T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/683,682 US5472850A (en) 1991-04-10 1991-04-10 Quantitative clotting assay for activated factor VII
PCT/US1992/002898 WO1992018870A1 (en) 1991-04-10 1992-04-09 Quantitative clotting assay for activated factor vii

Publications (2)

Publication Number Publication Date
DE69230183D1 DE69230183D1 (de) 1999-11-25
DE69230183T2 true DE69230183T2 (de) 2000-08-31

Family

ID=24745031

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69230183T Expired - Lifetime DE69230183T2 (de) 1991-04-10 1992-04-09 Quantitativer gerinnungstest für aktivierten faktor vii
DE0641443T Pending DE641443T1 (de) 1991-04-10 1992-04-09 Quantitativer Gerinnungstest für aktievierten Faktor VII.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE0641443T Pending DE641443T1 (de) 1991-04-10 1992-04-09 Quantitativer Gerinnungstest für aktievierten Faktor VII.

Country Status (10)

Country Link
US (3) US5472850A (de)
EP (1) EP0641443B1 (de)
JP (1) JP3047120B2 (de)
KR (1) KR940700679A (de)
AT (1) ATE185901T1 (de)
AU (1) AU663713B2 (de)
CA (1) CA2108282C (de)
DE (2) DE69230183T2 (de)
ES (1) ES2072243T3 (de)
WO (1) WO1992018870A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
ATE163768T1 (de) * 1991-10-04 1998-03-15 Dade Int Inc Herstellung von prothrombinzeit-reagenzien aus rekombinantem menschlichem gewebefaktor und sythetischen phospholipiden
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
WO1994007515A1 (en) * 1992-10-06 1994-04-14 The Scripps Research Institute Mutant tissue factor lacking factor vii activation activity
CA2154080C (en) 1993-01-29 2006-03-21 Bjorn Dahlback Novel anticoagulant cofactor activity
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US5766869A (en) * 1995-11-30 1998-06-16 Ahs Hospital Corp. Factor V ratio blood test for susceptibility to thromboembolism
US5839443A (en) * 1996-05-16 1998-11-24 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
US6132729A (en) 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
DE19714559C1 (de) * 1997-04-09 1998-08-06 Blutspendedienst Der Drk Lande Verfahren zur Bestimmung von aktivierten Blutgerinnungsfaktoren in Plasma und Plasmaderivaten
US6124110A (en) * 1997-04-09 2000-09-26 Drk-Blutspendedienst Nordrheinwestfalen Ggmbh Method for determining activated coagulation factors in plasma and plasma derivatives
AU7129598A (en) * 1997-04-23 1998-11-13 Instrumentation Laboratory S.P.A. Recombinant rabbit tissue factor based prothrombin time reagent
DE19720853A1 (de) * 1997-05-17 1998-11-19 Dade Behring Marburg Gmbh Erhöhung der FVII Empfindlichkeit eines Thromboplastinreagenzes
US6245573B1 (en) 1998-02-12 2001-06-12 University Of Medicine And Dentistry Of New Jersey Rapid assessment of the coagulant activity of blood
PT1056884E (pt) * 1998-02-27 2002-06-28 Pamgene Bv Processo para a amplificacao nao especifica de acido nucleico
AU3461999A (en) * 1998-04-01 1999-10-18 Trustees Of Columbia University In The City Of New York, The Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
JP2002517739A (ja) 1998-06-08 2002-06-18 ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ 血液および血液製剤における凝固の抑制
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
GB2358862B (en) * 1999-12-21 2004-07-21 Fermentron Ltd Processes for Extracting Carotenoids from Biomass Carotenoid Sources
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6743596B1 (en) * 2000-10-27 2004-06-01 Biomerieux, Inc. Method of determining global coagulability hemostatic potential
US7110118B2 (en) * 2000-12-19 2006-09-19 Trustees Of Boston University Spectral imaging for vertical sectioning
US6855509B2 (en) * 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
DE10064689B4 (de) * 2000-12-22 2004-08-05 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Verfahren zur Bestimmung der Blutzellhämostase
US6596543B2 (en) 2001-03-22 2003-07-22 Dade Behring Inc. Use of liposomes of defined composition and size for the preparation of prothrombin time reagents
EP1260817A3 (de) * 2001-05-08 2002-12-18 Warner-Lambert Company Methode zur Direktbestimmung von Koagulationsfaktor VIIa in Plasma
WO2003004694A1 (en) * 2001-07-03 2003-01-16 Oklahoma Medical Research Foundation ASSAY FOR MEASURING FACTOR VIIa-ANTITHROMBIN COMPLEXES
EP1432447A2 (de) * 2001-09-27 2004-06-30 The Board Of Regents, The University Of Texas System Kombinierte zusammensetzung und methoden zur behandlung der koagulation tumorgefäss
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PT1517698E (pt) * 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
AU2003290663A1 (en) * 2002-11-13 2004-06-03 Haematologic Technologies, Inc. Assay for tissue factor and factor viia
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
BRPI0409936A (pt) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
BRPI0413518A (pt) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
SI2298287T1 (en) * 2003-12-19 2018-08-31 Novo Nordisk Health Care Ag Stabilized compositions of factor VII polypeptides
US7148067B2 (en) * 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
US20080260858A1 (en) * 2005-02-16 2008-10-23 The Board Of Trustees Of The University Of Illnois Universal Procoagulant
JP2008531692A (ja) * 2005-03-04 2008-08-14 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 凝固及び線維素溶解カスケードのモジュレーター
FR2910969B1 (fr) * 2006-12-29 2009-02-27 Lab Francais Du Fractionnement Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon
WO2009046274A1 (en) * 2007-10-03 2009-04-09 The University Of Vermont And State Agriculture College Methods of detection of factor xia and tissue factor
US8821861B2 (en) * 2007-10-05 2014-09-02 The Board Of Trustees Of The University Of Illinois Fibrin sealant
WO2009061697A1 (en) * 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
DE102009048199A1 (de) * 2009-10-05 2011-04-21 Siemens Healthcare Diagnostics Products Gmbh Verfahren zur Bestimmung von Faktor XIII mit Hilfe von Referenzmaterial auf Plasmabasis
JP5851410B2 (ja) 2009-10-30 2016-02-03 シーエヌジェイ ホールディングス、インク． 組換えビタミンｋ依存性タンパク質の生成法
US20140038204A1 (en) * 2012-07-31 2014-02-06 Baxter Healthcare S.A. Selective measurement of active human protease coagulation factors
CN108474800B (zh) * 2016-01-07 2022-02-25 藤森工业株式会社 采血管、试剂及利用了它们的血液性状分析方法
JP6626761B2 (ja) * 2016-03-30 2019-12-25 シスメックス株式会社 プロトロンビン時間測定用試薬およびその製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479938A (en) * 1981-06-25 1984-10-30 Baxter Travenol Laboratories, Inc. Therapeutic composition containing factor VIIa
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
AU593042B2 (en) * 1985-11-26 1990-02-01 Novo Nordisk Health Care Ag Compositions and methods for the treatment of bleeding disorders
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
EP0321526A1 (de) * 1987-06-12 1989-06-28 Mount Sinai School Of Medicine Of The City University Of New York Klonierung und expression von humanem gewebefaktor
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Also Published As

Publication number Publication date
JP3047120B2 (ja) 2000-05-29
JPH06506601A (ja) 1994-07-28
US5750358A (en) 1998-05-12
CA2108282C (en) 2003-09-09
US5741658A (en) 1998-04-21
AU663713B2 (en) 1995-10-19
DE641443T1 (de) 1995-10-12
ES2072243T3 (es) 2000-03-16
AU1872992A (en) 1992-11-17
ES2072243T1 (es) 1995-07-16
DE69230183D1 (de) 1999-11-25
KR940700679A (en) 1994-02-23
EP0641443A1 (de) 1995-03-08
EP0641443B1 (de) 1999-10-20
ATE185901T1 (de) 1999-11-15
WO1992018870A1 (en) 1992-10-29
CA2108282A1 (en) 1992-10-11
US5472850A (en) 1995-12-05

Similar Documents

Publication Publication Date Title
DE69230183T2 (de) Quantitativer gerinnungstest für aktivierten faktor vii
Barrett Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates.
TWI256975B (en) Compositions containing a urea derivative dye for detecting an analyte and methods for using the same
PT984282E (pt) Particulas que tem incorporada uma composicao que compreende um composto quimioluminescente
AU751525B2 (en) Method for determining the anticoagulatory potential of a sample
EP0420332A3 (en) Method for determining the endogenous thrombin potential of plasma and blood, and also a kit or use in said method
DE3784589T2 (de) Verwendung von oxidase-enzymsystemen in chemilumineszierenden tests.
DE69118516D1 (de) Kolorimetrische enzymatische analyse
DK0690991T3 (da) Ny antikoagulant-cofaktor-aktivitet
DE3473475D1 (en) Process for determining substrate or enzymatic activity
CA2100567A1 (en) Protein S Chromogenic Assay
ATE107704T1 (de) Verfahren zur selbstdurchführung von enzymkinetik.
AU6385498A (en) Reagent for determining aptt
CA2037434A1 (en) Functional assay for determining the protein s activity
ATE208424T1 (de) Verwendung einer vanadin-bromperoxidase als ein signalgenerierendes enzym für chemilumineszierende systeme: testkits und analytische verfahren
MY104675A (en) Chromogenic substrate for esterase and immunoassay using same.
ATE274702T1 (de) Verwendung derivatisierter reagenzien in chemilumineszenz- und elektrochemilumineszenz- nachweisverfahren
MY104235A (en) High sensitivity detection of peroxidase activity.
DE69928541D1 (de) Luziferase assay, zusammensetzungen und testsätze zu damit in zusammenhang stehenden verwendungen
ATE91024T1 (de) Festphasenimmunoassayverfahren.
ES2011997A6 (es) Metodo de ensayar 2-bromo-2nitro-1,3-propandiol o sus derivados y equipo de ensayo correspondiente.
ES2087892T3 (es) Utilizacion de la superoxido dismutasa en ensayos que implican una oxidasa.
DE69331708D1 (de) Von enzymen katalysierte chemilumineszente detektion von proteinen und nukleinsäuren durch verwendung von hydroxyaryl-cyclischen diacylhydrazid-zusammensetzungen
UA33566A (uk) Спосіб кількісного визначення ципрофлоксацину

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 641443

Country of ref document: EP